- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01587079
Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
23. maj 2016 opdateret af: Pearl Therapeutics, Inc.
A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
159
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Arizona
-
Glendale, Arizona, Forenede Stater
- Pearl Investigative Site
-
-
California
-
Rancho Mirage, California, Forenede Stater
- Pearl Investigative Site
-
-
Connecticut
-
Waterbury, Connecticut, Forenede Stater
- Pearl Investigative Site
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33765
- Pearl Investigative Site
-
Clearwater, Florida, Forenede Stater
- Pearl Investigative Site
-
Pensacola, Florida, Forenede Stater
- Pearl Investigative Site
-
Winter Park, Florida, Forenede Stater, 32789
- Pearl Investigative Site
-
-
Louisiana
-
Lafayette, Louisiana, Forenede Stater
- Pearl Investigative Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Forenede Stater
- Pearl Investigative Site
-
-
Minnesota
-
Fridley, Minnesota, Forenede Stater
- Pearl Investigative Site
-
-
Missouri
-
St. Louis, Missouri, Forenede Stater
- Pearl Investigative Site
-
-
New Jersey
-
Summit, New Jersey, Forenede Stater
- Pearl Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater
- Pearl Investigative Site
-
-
Oregon
-
Medford, Oregon, Forenede Stater, 97504
- Pearl Investigative Site
-
Medford, Oregon, Forenede Stater
- Pearl Investigative Site
-
-
South Carolina
-
Rock Hill, South Carolina, Forenede Stater
- Pearl Investigative Site
-
Spartanburg, South Carolina, Forenede Stater, 29303
- Pearl Investigative Site
-
-
Texas
-
San Antonio, Texas, Forenede Stater
- Pearl Investigative Site
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater
- Pearl Investigative Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
40 år til 80 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Key Inclusion Criteria:
- Signed written informed consent
- 40 - 80 years of age
- Clinical history of COPD with airflow limitation that is not fully reversible
- Females of non-child bearing potential or females of child bearing potential with negative pregnancy test and acceptable contraceptive methods
- Current/former smokers with at least a 10 pack-year history of cigarette smoking
- A measured post-bronchodilator FEV1/FVC ratio of < or = 0.70
- A measured post-bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
- Able to change COPD treatment as required by protocol
Key Exclusion Criteria:
- Women who are pregnant or lactating
- Primary diagnosis of asthma
- Alpha-1 antitrypsin deficiency as the cause of COPD
- Active pulmonary diseases
- Prior lung volume reduction surgery
- Abnormal chest X-ray not due to the presence of COPD
- Hospitalized due to poorly controlled COPD within 3 months of Screening
- Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
- Cancer that has not been in complete remission for at least 5 years
- Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives
Other inclusion/exclusion criteria as defined in the protocol
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: PT003 (dosis 1)
PT003 MDI dosis 1
|
PT003 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT003 (dosis 2)
PT003 MDI dosis 2
|
PT003 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT003 (dosis 3)
PT003 MDI dosis 3
|
PT003 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT003 (dosis 4)
PT003 MDI dosis 4
|
PT003 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT003 (Dose 5)
PT003 MDI Dose 5
|
PT003 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT001
PT001 MDI
|
PT001 MDI indgivet som to pust BID i 7 dage
|
Eksperimentel: PT005
PT005 MDI
|
PT005 MDI indgivet som to pust BID i 7 dage
|
Aktiv komparator: Spiriva® Handihaler®
Tiotropium Bromide
|
Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
FEV1 AUC 0-12 on Day 7
Tidsramme: Day 7
|
FEV1 AUC 0-12
|
Day 7
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Peak Change From Baseline in FEV1 on Treatment Day 1
Tidsramme: Day 1
|
Peak change from Baseline in FEV1 on Treatment
|
Day 1
|
Time to Onset of Action (>10% Improvement in FEV1) on Day 1
Tidsramme: Day 1
|
Time to onset of action (>10% improvement in FEV1)
|
Day 1
|
Proportion of Subjects Achieving >=12% Improvement in FEV1 on Day 1
Tidsramme: Day 1
|
Proportion of subjects achieving >=12% improvement in FEV1
|
Day 1
|
Peak Change From Baseline in Inspiratory Capacity on Day 1
Tidsramme: Day 1
|
Peak change from baseline in Inspiratory Capacity
|
Day 1
|
Change From Baseline in Morning Pre-dose Trough FEV1 on Day 7
Tidsramme: Day 7
|
Change from baseline in morning pre-dose trough FEV1
|
Day 7
|
Peak Change From Baseline in FEV1 on Day 7
Tidsramme: Day 7
|
Peak change from baseline in FEV1 Day 7
|
Day 7
|
Change From Baseline in Morning Pre-dose Trough IC on Day 7
Tidsramme: Day 7
|
Change from baseline in morning pre-dose trough IC
|
Day 7
|
Peak Change From Baseline IC on Day 7
Tidsramme: Day 7
|
Peak change from baseline IC
|
Day 7
|
Change From Baseline at Evening 12-hour Post-dose Trough FEV1 on Day 7
Tidsramme: Day 7
|
Change from baseline at evening 12-hour post-dose trough FEV1
|
Day 7
|
Change From Baseline in Mean Morning Pre-dose Daily Peak Flow Readings on Day 7
Tidsramme: Day 7
|
Change from baseline in mean morning pre-dose daily peak flow readings
|
Day 7
|
Change From Baseline in Mean Morning Post-dose Daily Peak Flow Readings on Day 7
Tidsramme: Day 7
|
Change from baseline in mean morning post-dose daily peak flow readings on
|
Day 7
|
Change From Baseline in Mean Evening Pre-dose Daily Peak Flow Readings on Day 7
Tidsramme: Day 7
|
Change from baseline in mean evening pre-dose daily peak flow readings (BID treatments only)
|
Day 7
|
Change From Baseline in Mean Evening Post-dose Daily Peak Flow Readings on Day 7
Tidsramme: Day 7
|
Change from baseline in mean evening post-dose daily peak flow readings (12 Hours post-dose for Spiriva)
|
Day 7
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Colin Reisner, MD, Pearl Therapeutics, Inc.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2012
Primær færdiggørelse (Faktiske)
1. september 2012
Studieafslutning (Faktiske)
1. oktober 2012
Datoer for studieregistrering
Først indsendt
25. april 2012
Først indsendt, der opfyldte QC-kriterier
26. april 2012
Først opslået (Skøn)
27. april 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
30. juni 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. maj 2016
Sidst verificeret
1. maj 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Lungesygdomme
- Lungesygdomme, obstruktiv
- Lungesygdom, kronisk obstruktiv
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Parasympatholytika
- Autonome agenter
- Agenter fra det perifere nervesystem
- Kolinerge antagonister
- Kolinerge midler
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Tiotropiumbromid
Andre undersøgelses-id-numre
- PT003005
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med PT003
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.Afsluttet
-
Pearl Therapeutics, Inc.AfsluttetKronisk obstruktiv lungesygdomForenede Stater, Tyskland, Det Forenede Kongerige, Kina, Taiwan, Korea, Republikken, Japan, Tjekkiet, Ungarn, Polen, Den Russiske Føderation
-
Pearl Therapeutics, Inc.Afsluttet